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Abstract Diabetes is usually classified as autoimmune or
metabolic but, as difficulties have arisen with the taxonomy
of diabetes, it may help to forego the conventional classifica-
tion for a more inclusive model. Thus, all diabetes can be
ascribed to beta cell insufficiency—hyperglycemia occurs
only when the insulin supply fails to meet demand. Humans
enter the world with a reserve of beta cells, which is eroded
variably by apoptosis over the course of a lifetime. For most,
the loss is slow and inconsequential but, for others fast enough
to be critical within a lifetime. The challenge now is to define
the factors that vary the tempo of beta cell loss, because
tempo, not type, seems likely to determine whether diabetes
occurs at all, in adulthood or in childhood. Insulin resistance is
generally believed to underpin T2D, but has been a feature of
insulin-dependent diabetes as well for nearly 80 years, though
largely ignored until immunotherapy trials to test the autoim-
munity hypothesis persistently failed to bring patient benefit.
It seems possible that insulin resistance accelerates beta cell
loss generally, its impact modulated by an immune response
(autoimmunity) to the beta-cell stress whose intensity varies
with immunogenotype. If so, the target for prevention of T1D
might more logically lie with insulin sensitivity than with
immunoregulation.
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Introduction
The categorization of diabetes into type 1 (T1D, autoimmune)
and type 2 (T2D, metabolic) is a relatively recent construct.
Insulin resistance is generally accepted to underpin the path-
ogenesis of T2D, and insulin resensitization can make an
important contribution to its management. The rise in the
incidence of T2D over recent years, and its ever earlier age
at presentation tends to have dominated the field, yet T1D has
behaved in an exactly parallel manner. The similarity of
behavior, and the disappointing results of immunotherapy
trials designed to test the autoimmune paradigm, have togeth-
er raised questions as to whether autoimmunity drives T1D, or
possibly insulin resistance.
Background
Himsworth was the first to describe insulin resistance in
diabetes nearly 80 years ago [1], but not, as is often
thought, to distinguish adults from juveniles with the
disease—insulin resistance was noted in both [2]. Others
repeated Himsworth’s observations using simple insulin-
glucose tolerance tests [3–5], until a more sophisticated
measure of insulin sensitivity, the glucose clamp, provided
direct evidence that impaired insulin action is also ‘….a
common feature of type 1 diabetes’ [6]. Indeed, Elliott
Joslin concluded that, while it was possible to separate
patients according to insulin sensitivity, the overlap in their
clinical phenotypes was so great as to make testing for it of
little help [7]. Thus, insulin resistance was widely reported
in juvenile diabetes form earliest times, but there seemed
few implications and the unity of diabetes remained
unchallenged.
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Observation vs Experiment
Diabetes remained a single disorder until the 1970s, when 3
observations made largely in children (lymphocytic insulitis
[8], islet cell antibodies [9], and HLA genotype [10]) were
interpreted by opinion leaders at the time to mean that child-
hood diabetes, unlike adult diabetes, was caused by
dysregulation of the immune system (autoimmunity). A pre-
viously single disorder was now viewed as 2 categorically
distinct entities of different etiology, and the autoimmune
paradigm has become deeply rooted since. Importantly, how-
ever, the new classification into type 1 (autoimmune) and type
2 (metabolic) diabetes was based on observation, not on
experiment. Some 20 human trials using immunotherapy to
test the autoimmunity paradigm have since met with little
success [11••], and none has translated into patient benefit.
The relationship of insulin resistance to autoimmunity has
only been raised in recent time because of mounting concern
that the original interpretation may not have been correct [12].
Autoimmunity is clearly present in T1D, but its primacy in the
sequence of events is being questioned. Rather than the driver
of beta cell loss, ‘autoimmunity’ may be the response of a
normal immune system to islets, which are stressed by the
demands of insulin resistance [13].
The wealth of experimental data cited in support of the
autoimmunity hypothesis for T1D is largely drawn from pre-
vention studies in animal models. Such studies are frequently
successful, but animals are not human, and biomedical re-
search is often confronted with hypotheses that worked in
animals, but not in humans. In the case of T1D, the models
are not just animals, but animals abnormal to the point where
they fail to develop diabetes unless their environment is rig-
idly controlled. The models most used in T1D research, the
NOD mouse and Biobreeding rat, are inbred for immunoge-
netic deficiencies that are not part of the human disease, but
essential to the model [14]. Such models show that the im-
mune system can destroy the beta cells of inbred rodents, but
say little about the mechanisms responsible for T1D in out-
bred humans. The extensive and often elegant evidence from
animals has nevertheless served to sustain the momentum of
immunotherapy in human trials, and a clinical classification
for which there is little human evidence.
The Curse of Classification
Categorization has a prominent place in clinical medicine,
because it enables doctors – and increasingly nurse specialists
– to treat according to protocol. T1D is treated with insulin
because it is classified as ‘insulin-dependent’ and type 2 with
diet and/or hypoglycemic agents because it is ‘insulin-inde-
pendent’. But classification can also obfuscate. As Edwin
Gale points out, ‘…classification may come to embody
outworn concepts that prevent us from seeking or applying
new information we need…. Does it act as a stimulus for
thought, or a substitute for it?’[12]. One difficulty with clas-
sification is the way it systematically ignores findings that
don’t fit – ‘orphan’ observations. The classification of diabe-
tes into type 1 and type 2 has run into difficulties in recent
times [15], yet remains intact because evidence that doesn’t fit
is often ignored. Thus, islet-related autoantibodies, which
have for decades been the exclusive hallmark of T1D, are
regularly reported in patients whose phenotype is type 2 [16,
17]. The categorization of T1D as childhood or juvenile is
patently suspect, when more than half of new cases present in
adulthood [18], toddlers who go on to develop T1D are
heavier than their peers [19], not lighter as the diabetes tradi-
tion would have it, ….and insulin resistance, long since the
basis for T2D, was noted decades ago to be a ‘common
feature’ of T1D [6]. The classification of T1D as an autoim-
mune disorder of childhood, and type 2 as a metabolic disor-
der of later life has become deeply rooted in the teaching of
diabetes, its literature, its clinical practice, and even its re-
search funding. Doubts nevertheless linger, doubts that relate
primarily to the relationship between insulin resistance and
autoimmunity.
Doubts
Concerns over the duality of diabetes first emerged through
epidemiology, though few noted their significance at the time.
Yemenite immigrants to Israel in the 1950s suffered very little
diabetes but, after 25 years in a land of plenty, experienced a
40-fold increase in its prevalence. Intriguingly, it wasn’t just
T2D – the proportion of insulin dependency among people
with newly diagnosed T1D was similar to that among Israelis
of European origin [20]. The observation is fundamentally
important, because it suggests a common driver for both major
forms of diabetes. Again, it is seldom remarked upon, but
clearly documented, that wherever in the world there has been
a rise in T2D, there has been a corresponding increase in T1D
[21], and many studies report how the frequency of T1D
among the relatives of those with T2D is many times greater
than that in the general population [22, 23].
The possibility that autoimmunity might be a physiological
response to beta cell stress, rather than its pathological cause,
was addressed some 25 years ago [24], in the wake of Pierre
Grabar’s seminal papers on the immune system’s primordial
role as housekeeper, clearing up the detritus of apoptotic (and,
where needed, necrotic) cell death [25]. Being shape-specific
and clonal, the immune system was ideally adapted to expand
and contract in response to specific housekeeping need. What
to others before him had been a canon of absolute tolerance to
self antigens, was to Grabar the absence of a technology
sufficiently sensitive at the time to detect a natural process
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of waste removal – until it was intense, when it was given the
label ‘autoimmunity’ in order to comply with the tolerance
paradigm [26]. Grabar’s great contribution was to breach the
doctrine of self-tolerance that had previously obliged autoim-
munity to be viewed as pathology. His concept of autoimmu-
nity as a physiological, if vigorous, ‘housekeeping’ reaction to
stressed and rapidly apoptosing cells in people with particu-
larly reactive immune response genes, points to its place in
diabetes as effect rather than cause. Autoimmunity is never-
theless inflammatory, and may be expected to further acceler-
ate apoptotic death of the beta cell.
An Alternative Paradigm
In most individuals, insulin resistance increases with aging
[27], and demand for insulin accelerates the apoptosis of beta
cells. As a result, the beta cell mass declines progressively
over a lifetime but, for most, the loss is inconsequential
because it is slow and the reserve substantial. The mechanisms
have been recently reviewed [28]. Longer life expectancy will
of itself mean a higher burden of diabetes as more people
survive to breach the threshold, but only acceleration of the
beta cell loss will shift its demography. Only tempo can
explain how T2D, which a generation ago was confined to
middle age and beyond, has now become the fastest growing
chronic disorder of childhood and how T1D, for decades a
disorder of adolescence, is now rising fastest in the under 5-
year olds [29].
Insulin resistance, largely (but not exclusively) the result of
excess weight gain, is generally believed to drive T2D.
Upregulation, and the glucotoxicity and lipotoxicity that result
from the metabolic disturbance associated with insulin resis-
tance, are believed to stress the beta cell [30–32]. It has been
known for 40 years that children who develop T1D—far from
being undernourished and of low body mass—are heavier as
toddlers than their peers who do not [19], and weight gain is a
feature of childhood generally over recent time. The link
between early weight gain and T1D resurfaced during the
1990s [33–35], and in 2001 the accelerator hypothesis pro-
posed that insulin resistance, rather than autoimmunity, was
the driver of T1D – Type 1 and type 2 diabetes are the same
disorder of insulin resistance, set against different back-
grounds. The link to body weight is emphasized by a recent
meta-analysis which found in all the studies it reviewed that
people with T1D showed greater weight gain during the first
year of life compared with controls [36•]. Crucially, the accel-
erator hypothesis does not dismiss autoimmunity. Rather,
autoimmunity is deemed to be a response to beta cell stress,
rather than its cause, and inflammatory in its own right. The
hypothesis is conceptually simple, but potentially important if
it resets the target for prevention of childhood diabetes from
the immune system to insulin resistance.
Rising demand is the driver which stresses the beta cells,
and the immune response is a secondary accelerator operating
in those with particular HLA genotypes (eg, HLA DR3/DR4).
The probability of developing diabetes reflects an infinitely
variable interaction between level of demand and intensity of
immune response (Fig. 1). Only a small change in demand
may be needed to precipitate diabetes where the immune
response to it is intense, while diabetes may never develop
in the most insulin resistant individual whose immune re-
sponse is weak.
Rather than categories diabetes into types 1 and 2 (or 1½,
Double, LADA, or LADY), the accelerator hypothesis sees a
continuous spectrum defining a single process, which pro-
gresses at different rates, from ‘no’ diabetes (most people)
through ‘slow’ diabetes (adulthood) to ‘fast’ diabetes
(childhood) (Fig. 2). Adult diabetes is not a type of diabetes,
but diabetes in adulthood, just as childhood diabetes is not
itself an entity, but diabetes in childhood. Time travels in 1
direction only so that, inevitably, those whose genotype en-
codes the most intense immune response present earliest in
life. The variation in diabetes is one of tempo, not of type.
Evidence
Evidence to justify reconsideration of the relationship between
autoimmunity and insulin resistance has been detailed in a
number of reviews [15, 37–40, 41•]. It moves from the indi-
rect to the direct, but remains, for the moment, short of
experimental. A hypothesis proposing that insulin resistance
was the driver for T1D could not be sustained unless there was
a rise in T1D which paralleled that of obesity, the single most
important causal factor of insulin resistance. There are many
such reports, though their importance lies not in arguing
association, which is always vulnerable to ecological fallacy,
but in their sine qua non. The hypothesis would sink without
them.
An appropriate temporal association between weight gain
and T1D is also a sine qua non. The weight gain must come
first if it is to contend for the role of causation, and reference
was made earlier to several reports that children who develop
T1D are heaver (and taller) than their peers years in advance of
clinical presentation.
Of greater importance, though still not proof of causality, is
the inverse correlation between BMI and age at presentation in
populations of children with T1D. Correlation is evidence of
systematic association between variables within a population
rather than merely parallel behavior between 2 groups. In this
instance, the evidence is for acceleration of diabetes onset in
heavier children.
There are 2 contributions to the probability of developing a
multifactorial disease such as T1D – environmental risk and
genetic susceptibility to it. The 2 relate inversely to each other
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so that if the risk rises, the proportion of probability attribut-
able to susceptibility must fall. There is good epidemiological
evidence that the genetic contribution to the probability of
T1D has fallen over recent years [42, 43], implying that the 3-
fold rise since the 1980s is related to environmental change.
Such evidence does not indicate what environmental change,
and has to be interpreted sparingly on that account.
There are several reports, spanning decades, of insulin
resistance among patients with insulin-dependence and, more
recently, among patients with pre-T1D. Where insulin resis-
tance was once an irrelevance to the pathophysiology of
diabetes, it became for a time part of its duality. Increasing
difficulties with matching the modern phenotype of diabetes
with the criteria for its classification, and the disappointing
results of immunotherapy prevention trials have led to some
re-thinking and a reconsideration of the relationship between
insulin resistance and autoimmunity.
Refutation
Paradigm change is challenging, and careful consideration
should be given to arguments that seek to refute it. One early
concern from geneticists was the lack of overlap between loci
associated with T1D and those associated with type 2. How
could the two be one and the same disease if they do not share
susceptibility genes? This is a particularly genocentric posi-
tion to adopt because, apart from monogenic states, genes do
not cause disease. In multifactorial disorders, genes merely
modulate risk – in this case the rate of beta cell loss – and
Fig. 1 is an attempt to schematize the relationship between risk
(environment) and susceptibility (genes). Indeed, the acceler-
ator hypothesis from its inception proposed that ‘…type 1 and
T2D are the same disorder of insulin resistance set against
different genetic backgrounds.’ By implication, those who
succumb to diabetes early in life will carry ‘fast’ genes and
those later in life, ‘slow’ genes (Fig. 2).
Two reports examined existing data sets opportunistically,
concluding that the inverse relationship between BMI and age
at presentation of T1D that defines acceleration was apparent
only in children whose beta cell loss was already well ad-
vanced [44, 45]. However, in contrast to other studies, which
incorporated whole clinic populations collected over decades,
the 2 in question (SEARCH and ENDIT) analyzed children
who had become diabetic during a brief window of time, and
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Fig. 1 The probability of
developing diabetes – an
infinitely variable interaction
between insulin demand and
immunogenetic response
(autoimmunity). (With
permission from: Wilkin TJ. The
convergence of type 1 and type 2
diabetes in childhood: the
accelerator hypothesis. Pediatric
Diabetes. 2012;13:334–9.) [41•]
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Fig. 2 The concept of tempo in diabetes. (With permission from: Wilkin
TJ. The convergence of type 1 and type 2 diabetes in childhood: the
accelerator hypothesis. Pediatric Diabetes. 2012;13:334–9.) [41•]
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for that reason may have selectively excluded children with
less aggressive (slower) disease.
Another concern is why, if T1D and T2D are the same
disorder, their insulin requirements are typically so different.
An explanation might again be drawn from Fig. 1, and its
representation of the infinitely variable interaction between
beta cell load (insulin resistance) and immunogenetic re-
sponse. Insulin requirement reflects not only beta cell reserve,
but tissue sensitivity, and sensitivity clearly affects endoge-
nous as much as administered insulin. Children with the
highest susceptibility need only a small increase in beta cell
load to mount the immune response that destroys their islets,
and a correspondingly small dose of insulin in replacement.
Lower susceptibility requires a higher load for diabetes to
develop and, if load is now the major contributor to beta cell
loss, the therapeutic dose required is likely to be higher. That
said, it is a common experience to have required only small
doses of insulin as a relatively slim child with ‘fast’ diabetes,
but higher doses as a heavier adult. The same explanation
might be directed toward another clinical difference that some
believe distinguishes T1D from T2D—brittleness. Fluctuant
control (variable blood sugar) should be differentiated from
poor control (raised blood sugar). The latter is often associated
with loss of tissue sensitivity, whereas brittleness, although
multifactorial, generally needs tissue sensitivity. Children,
who for the most part develop fast diabetes where the immune
response is dominant, and adults with T1D who remain slim,
tend to be more vulnerable to brittleness, whereas those whose
diabetes develops slowly because insulin demand is dominant,
tend not to be.
It is sometimes asked how T1D and T2D can be the same
disorder, when autoimmune diabetes is associated with the
autoimmune regulator gene (AIRE) [46], while type 2 is not.
Mutations of AIRE, however, are implicated only in the rare
polyglandular disorder of the autoimmune-polyendocrinopathy-
candidiasis-ectodermal dystrophy (APECED) syndrome, of
which diabetes sometimes forms part [47]. Thus, dysregulation
of the immune system by a single gene mutation can lead to
autoimmunity as a primary cause of diabetes in man, as it can in
the NOD mouse, but AIRE mutations are not found in
nonsyndromic T1D [48] and do not seem relevant to the accel-
erator hypothesis.
APT – Accelerator Prevention Trials
It is now a decade since the author and a number of interna-
tional colleagues called for alternative approaches to that of
immunotherapy in the prevention of T1D in children [49].
Attitudes towards the relationship of insulin resistance to
autoimmunity have changed over this period, with a number
of reports world-wide confirming the predictions of the accel-
erator hypothesis, and others providing direct evidence for
insulin resistance in children at risk of T1D. The weight of
circumstantial evidence for the accelerator concept, and the
disappointing outcome of immunotherapy trials, have this
year (2013) led an international funding agency to consider
a multi-stage intervention trial to reduce beta cell load in
children at risk of T1D. The outcome of stage 1, if funded,
will be known in late 2015.
Conclusions
Hyperinsulinemia resulting from insulin resistance appears to
precede all forms of diabetes except for the single gene disor-
ders of glucose sensing or insulin release. Nature’s weight
gain experiment of the past 40 years—almost certainly the
largest ‘clinical trial’ of recorded time—has been associated
with an exponential rise in insulin resistance, and in T1D as
well as T2D [50]. Hypotheses need mechanisms to guide the
interventions used to test them. The issues here are whether
there is now sufficient evidence to justify an intervention
study based on the accelerator principle and sufficient benefit
to be expected from the outcome. The hypothesis that T1D
and T2D are the same disorder has a mechanism to explain it,
but so far only circumstantial evidence to support it. The
perceived outcome—reclassification of diabetes as a single
entity—might strengthen resolve to redirect resources toward
the prediabetic state, where the opportunity for prevention
surely lies. A single disorder, targeting a single issue (insulin
resistance) for prevention, could have considerable impact on
the burgeoning problem of childhood diabetes.
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